阿瑞匹坦用于晚期乳腺癌化疗的止吐效果观察  被引量:5

Efficacy of Aprepitant in Treatment of Chemotherapy-induced Nausea and Vomiting in Patients with Advance Breast Cancer

在线阅读下载全文

作  者:姜敏[1] 迟峰[1] 曾越灿[1] JIANG Min CHI Feng ZENG Yue-can(Department of Oncology, Shengjing Hospital Affiliated to China Medical University, Liaoning 110022, China)

机构地区:[1]中国医科大学附属盛京医院肿瘤科,沈阳110022

出  处:《临床误诊误治》2017年第3期95-98,共4页Clinical Misdiagnosis & Mistherapy

摘  要:目的观察阿瑞匹坦对晚期乳腺癌患者应用含顺铂化疗方案后止吐效果及安全性。方法选取我院2014年1月—2016年5月使用含顺铂化疗方案的晚期乳腺癌56例,按照随机数字表法分为观察组及对照组,每组各28例。观察组于化疗首日用药前1 h口服阿瑞匹坦125 mg/d,第2、3天晨起口服阿瑞匹坦80 mg/d,同时予格拉司琼、地塞米松各5 mg/d静脉推注;对照组予安慰剂、格拉司琼及地塞米松,剂量及方法与观察组相同。结果两组急性恶心、迟发性恶心、急性呕吐、迟发性呕吐、急性恶心并呕吐发生率比较差异无统计学意义(P>0.05);与对照组比较,观察组迟发性恶心并呕吐发生率降低,差异有统计学意义(P=0.043)。观察组无恶心呕吐17例,对照组无恶心呕吐9例,差异有统计学意义(P<0.05)。两组其他不良反应比较差异无统计学意义(P>0.05),且阿瑞匹坦未发生相关中重度药物不良反应。结论阿瑞匹坦对应用含顺铂化疗方案的晚期乳腺癌患者止吐效果好,安全性高。Objective To observe efficacy and safety of Aprepitant in treatment of chemotherapy-induced nausea and vomiting in advanced breast cancer patients treated with Cisplatin. Methods A total of 56 advanced breast cancer patients treated with Cisplatin during January 2014 and May 2016 were divided into observation group (n = 28 ) and control group (n = 28) according to random digits table method. Observation group was treated with 125 mg/d Aprepitant one hour before medi- cation on the first day of chemotherapy, and 80 mg/d Aprepitant was taken orally in the morning on the 2sd and 3rd days, and 5 mg/d Granisetron and 5 mg/d Dexamethasone were given by intravenous push at the same time. Control group was treated with placebo, Granisetron and Dexamethasone with the same dosage and method. Results There were no significant differ- ences in incidence rates of acute nausea, delayed nausea, acute vomiting, delayed vomiting and acute nausea and vomiting in the two groups ( P 〉 0.05 ). Compared with those in control group, incidence rate of delayed nausea and vomiting was signifi- cantly decreased in observation group (P = 0. 043). There were 17 patients without nausea or vomiting in observation group and 9 patients without nausea or vomiting in control group, and the difference was statistically significant (P 〈 0.05). There were no significant differences in other incidence rates of adverse reaction between the two groups ( P 〉 0.05 ) , and no moderate or severe adverse reaction was found by Aprepitant. Conclusion Aprepitant in treatment of chemotherapy-induced nausea and vomiting in advanced breast cancer patients treated with Cisplatin can achieve good effect and safety.

关 键 词:阿瑞匹坦 血清素5-HT3受体拮抗剂 乳腺肿瘤 止吐 

分 类 号:R737.9[医药卫生—肿瘤]

 

参考文献:

正在载入数据...

 

二级参考文献:

正在载入数据...

 

耦合文献:

正在载入数据...

 

引证文献:

正在载入数据...

 

二级引证文献:

正在载入数据...

 

同被引文献:

正在载入数据...

 

相关期刊文献:

正在载入数据...

相关的主题
相关的作者对象
相关的机构对象